Compare TEX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | KNSA |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | N/A | 2018 |
| Metric | TEX | KNSA |
|---|---|---|
| Price | $60.75 | $39.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $58.50 | $52.33 |
| AVG Volume (30 Days) | ★ 1.2M | 514.6K |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.34 | 0.47 |
| Revenue | ★ $5,344,000,000.00 | $597,973,000.00 |
| Revenue This Year | $7.02 | $61.60 |
| Revenue Next Year | $3.97 | $29.82 |
| P/E Ratio | ★ $25.87 | $82.68 |
| Revenue Growth | 4.60 | ★ 55.68 |
| 52 Week Low | $31.53 | $17.82 |
| 52 Week High | $62.23 | $44.42 |
| Indicator | TEX | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 73.05 | 39.56 |
| Support Level | $56.82 | $39.16 |
| Resistance Level | $62.23 | $43.00 |
| Average True Range (ATR) | 1.75 | 1.75 |
| MACD | 0.41 | -0.37 |
| Stochastic Oscillator | 83.49 | 26.38 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.